AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive
A patient who beat the odds for developing early-onset Alzheimer’s disease led to the discovery of a new protective genetic variant against the disease.
DuChemBio Co , Ltd & Life Molecular Imaging Announce Material Transfer And Clinical Supply Agreement for [18F]PI-2620 Tau PET Tracer prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Alzheimers Disease is a More Heterogeneous Condition Than Previously Considered by Karishma Abhishek on May 3, 2021 at 11:22 PM Lund University, as published in the journal Nature Medicine.
Alzheimer s disease (AD) is a neurodegenerative disease that leads to gradual memory loss and behavioral changes. It is characterized by the formation of beta-amyloid plaques and the tau proteins in the brain tissues, years before the actual symptoms occur.
The progression of this abnormal tau protein accumulation in the brain is a key marker for Alzheimer s. With the aid of an advanced medical imaging technique - PET technology, monitoring of toxic protein accumulation in the brain has become possible in recent times.
Life Molecular Imaging announces an ongoing collaboration with UCB for PI-2620, a novel tau imaging agent, for improved diagnosis of Progressive Supranuclear Palsy prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.